New search | Conferencedetail
Print view

Targeting Therapy of Alzheimer’s and Related Neurodegenerative Diseases

evvnt Platform / evvnt
Conference themes
Alzheimer’s disease (AD) is the most common age-dependent neurodegenerative disease, which affects over 5 million people in the US and over 35 million people worldwide. Currently, only four drugs are approved for alleviating symptoms in AD patients, and no new therapy has been approved for AD since 2003.
Professional congress organizer (PCO)
Fusion Conferences
Speakers: Riqiang Yan (Cleveland Clinic Lerner Research Institute), Peter St George-Hyslop (University of Toronto), Don Cleveland (University of California at San Diego), David Holtzman (Washington University) and many more.

Enquiries and Registration:
Mr. Conference Manager
General Medicine
Congress fees
USD 1.823,00
(Prices: Academic from: USD 1823.00, Industry from: USD 1823.00, Student from: USD 1534.00.)
Organizer contact info
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International promotes access to education and training for all regardless of social, geographic and national borders."

Österreichische Akademie der ÄrzteAnästhesie in Entwicklungsländern e. V.FFG - 7. EU-RahmenprogrammCharité International AcademyCenter of ExcellenceSwiss Tropical and Public Health InstituteAGEM - Arbeitsgemeinschaft Ethnomedizin e. V.AMREF - African Medical and Research Foundation


Give us your professional opinion

Start survey

Start survey